Effective 1 July 2009, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish nine new Collaborative Research Centres. This decision has just been made by the responsible Grants Committee of the DFG at its spring session in Bonn. The new centres will initially be funded for four years with a total of 73.6 million euros. In addition to this, the DFG will also provide 20 percent overhead funding for each centre for indirect costs incurred by the research projects. Research topics of the newly approved Collaborative Research Centres (Sonderforschungsbereiche, SFB) include the development of more-effective cancer treatments through better imaging processes, the spread of modern man from Africa to Western Eurasia and the research of new statistical models that can better model, predict and control complex technical processes.
Acculis Limited, the UK based specialist microwave ablation company based in Denmead, England, announced the clearance of its latest device for coagulating and killing unwanted tissue during surgery. The device, designed for coagulations at the surface of the tissue fires controlled high power microwave energy into the target area causing it to heat rapidly and the cells to die. Liver surgeons around the world are using the Acculis MTA System to address tumours inside the liver using its existing needle probes that take the microwave energy to the centre of tumours. Using the same control unit, this latest device allows surgeons to address deposits on the surface of the liver without using a needle.
Z-Cube Srl, the corporate venture arm of Zambon Company SpA, and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today that they have entered into a license agreement for Z-Cube to develop and commercialize an innovative nanotechnology drug delivery system for the treatment of pain. The technology was invented by Professor Elka Touitou from the Department of Pharmaceutics, Faculty of Medicine, at the Hebrew University of Jerusalem. Under the terms of the agreement, Z-Cube has received the worldwide exclusive right to develop and commercialize the technology for pain applications and will sponsor a research program to be conducted by Prof.
FDA on Tuesday posted on its Web site advertising guidelines for drugmakers and medical device manufacturers, offering suggestions on how to present risk information to health care professionals and consumers, the Wall Street Journal reports. Agency officials said the industry had asked for guidance on how to comply with its rules, which require a balanced presentation of a product's risk and effectiveness. Exclusion or minimization of risk information is the most commonly cited violation each year in FDA-issued warnings or enforcement letters. The new guidelines include detailed information on how aspects such as font, types of contrast and white space in print materials can appropriately present risk information.
Competitive Technologies, Inc. (NYSE Amex: CTT) announced today that CTT's pain therapy medical device will be used by clinical investigators at the Virginia Commonwealth University Massey Cancer Center for a Phase II independent clinical study. The study will examine the ability of CTT's U.S. FDA-cleared device to decrease pain associated with chemotherapy-induced peripheral neuropathy (CIPN). "We are very proud to be able to offer this breakthrough device for clinical research study at VCU Massey Cancer Center, a National Cancer Institute-designated center that helps lead our nation's cancer research agenda, " said John B. Nano, CTT's Chairman, President and CEO.
A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress. Findings from the first multicenter trial of the procedure, called radiofrequency ablation, could mean patients have an alternative to surgery for treating Barrett's esophagus. The procedure uses a scope inserted through the mouth to destroy the abnormal tissue. The investigators report their findings in the May 28 issue of the New England Journal of Medicine. "Patients with Barrett's esophagus can go on to develop esophageal cancer, " says Steven A.